Parenteral Nanoemulsions Loaded with Combined Immuno- and Chemo-Therapy for Melanoma Treatment.
ICOS-Fc
Intralipid®
combination therapy
melanoma
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
28 Nov 2022
28 Nov 2022
Historique:
received:
20
10
2022
revised:
22
11
2022
accepted:
26
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
12
12
2022
Statut:
epublish
Résumé
High-grade melanoma remains a major life-threatening illness despite the improvement in therapeutic control that has been achieved by means of targeted therapies and immunotherapies in recent years. This work presents a preclinical-level test of a multi-pronged approach that includes the loading of immunotherapeutic (ICOS-Fc), targeted (sorafenib), and chemotherapeutic (temozolomide) agents within Intralipid
Identifiants
pubmed: 36500861
pii: nano12234233
doi: 10.3390/nano12234233
pmc: PMC9740980
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondazione CRT
ID : 2019.2252
Organisme : Italian Association for Cancer Research
ID : IG20714
Organisme : Fondazione Amici di Jean (Torino)
Organisme : Fondazione Veronesi
Organisme : Fondazione Cariplo
ID : 2017-0535
Organisme : University of Turin
ID : Ricerca Locale 2019-2021
Références
Cancer Immunol Res. 2014 Mar;2(3):194-9
pubmed: 24778315
Invest New Drugs. 2012 Dec;30(6):2096-102
pubmed: 22089297
Lab Invest. 2011 Apr;91(4):598-608
pubmed: 21321535
Int J Mol Sci. 2018 Aug 19;19(8):
pubmed: 30126252
Cancers (Basel). 2020 May 09;12(5):
pubmed: 32397484
Nature. 1999 Jan 21;397(6716):263-6
pubmed: 9930702
Cancer Lett. 2006 Nov 28;244(1):42-52
pubmed: 16412562
Int J Pharm. 2008 Aug 6;360(1-2):115-21
pubmed: 18508212
AAPS PharmSciTech. 2010 Dec;11(4):1526-40
pubmed: 20976577
Tumour Biol. 2019 Apr;42(4):1010428319837138
pubmed: 30957676
Int J Nanomedicine. 2016 May 25;11:2329-43
pubmed: 27307733
Commun Biol. 2020 Oct 26;3(1):615
pubmed: 33106594
Eur J Immunol. 2006 Oct;36(10):2601-12
pubmed: 17013990
Surg Clin North Am. 2020 Feb;100(1):175-188
pubmed: 31753111
J Immunol. 2013 Feb 1;190(3):1125-34
pubmed: 23275603
Mol Clin Oncol. 2013 Jan;1(1):29-34
pubmed: 24649118
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Mol Cancer Ther. 2008 Oct;7(10):3129-40
pubmed: 18852116
Drugs Context. 2012 Nov 19;2012:212242
pubmed: 24432031
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Int Immunopharmacol. 2016 Oct;39:273-279
pubmed: 27500457
Eur J Immunol. 1996 Nov;26(11):2781-9
pubmed: 8921969
Nanotechnology. 2015 Jan 26;26(25):255102
pubmed: 26043866
Clin Cancer Res. 2009 Aug 1;15(15):4838-46
pubmed: 19638466
Immunity. 2014 May 15;40(5):734-46
pubmed: 24837102
Clin Cancer Res. 2009 Dec 15;15(24):7711-7718
pubmed: 19996224
Theranostics. 2022 Jan 1;12(1):207-231
pubmed: 34987642
J Invest Dermatol. 2007 Oct;127(10):2399-410
pubmed: 17495956
Int J Mol Sci. 2018 Jan 24;19(2):
pubmed: 29364157
Acta Biomater. 2021 May;126:372-383
pubmed: 33774199
Anal Bioanal Chem. 2013 Nov;405(29):9351-63
pubmed: 24121431
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Pharmaceutics. 2021 Oct 04;13(10):
pubmed: 34683910
Eur J Immunol. 1999 Sep;29(9):2863-74
pubmed: 10508261
Cancer Res. 2011 Aug 15;71(16):5445-54
pubmed: 21708958
Immunol Rev. 2009 May;229(1):101-13
pubmed: 19426217
J Control Release. 2020 Apr 10;320:112-124
pubmed: 31962094